pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,407 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1211Endpoints917BioPharma Dive354BioSpace335Fierce Biotech314onclive165raps111globenewswire health73
therapy area
allOncology8088Rare Disease1924Cardiology1869Immunology1543Hematology1353Vaccines1251Pulmonology
  • Investors at Boston Digital Healthcare Innovation Summit focus on emerging health tech opportunities
    The reporter attended the Digital Healthcare Innovation Summit in Boston earlier this week, gaining a firsthand view of investor perspectives on health technology. Attendees heard that investors a…
    Endpoints · 4mo agoNeutral↗ source
  • Trump withdraws Casey Means as surgeon general nominee, names radiologist Nicole Saphier
    The Trump administration has withdrawn its nomination of Casey Means to serve as the next surgeon general. Means had been backed by the Make America Healthy Again movement, which sees the decision…
    STAT · 4mo agoNegative↗ source
← prev
page 131 of 137
next →
fda recalls71
fda medwatch62
fda press38
1248
Psychiatry & CNS882
Ophthalmology520
Pain501
Endocrinology & Metabolism493
Infectious Disease456
New data link rising wildfire smoke to greater health risks, while FDA confirms infant formula safety
Recent analyses show that smoke from increasingly frequent wildfires is contributing to higher levels of air pollution, which researchers say is linked to a range of adverse health outcomes. The U…
STAT · 4mo agoNeutral↗ source
  • The R&D 15: How pharma's top companies spent, won and lost on drug research
    Talking over pharma pipelines with a major drugmaker's development chief, he noted that if you looked at the biggest 50 drugs by revenue, the final one on the list brought in about $4 billion last ...
    Endpoints · 4mo agoNeutral↗ source
  • Data show international medical graduates are not displacing U.S. doctors in 2026 residency match
    The opinion piece examines a social‑media narrative that International Medical Graduates (IMGs) are taking residency slots away from U.S. medical graduates. The authors cite the 2026 Main Residenc…
    STAT · 4mo agoNeutral↗ source
  • Supreme Court hints skinny labeling may remain viable for generic drugs
    At a hearing, Supreme Court justices heard arguments about skinny labeling, a practice used by generic manufacturers to seek approval for a subset of a brand drug's indications. The justices did n…
    STAT · 4mo agoRegulatoryPositive↗ source
  • AbbVie's Skyrizi sales growth raises investor worries about J&J competition
    During AbbVie's first-quarter earnings call, analysts focused on the company's immunology franchise and asked how it would defend Skyrizi against emerging competition from Johnson & Johnson. The c…
    Endpoints · 4mo agoEarningsNegative↗ source
  • FDA, AstraZeneca prep for oncology adcomm
    The FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...
    Endpoints · 4mo ago↗ source
  • STAT+: Why conversations around health AI may be evolving beyond hype
    In this edition of AI Prognosis, Brittany Trang argues that the tide may be turning when it comes to how the health care industry talks about AI.
    STAT · 4mo ago↗ source
  • Teva nabs experimental Tourette drug in $700M Emalex buyout
    A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
    BioPharma Dive · 4mo ago↗ source
  • Chiesi to buy KalVista in $1.9B deal for rare disease drug
    The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
    BioPharma Dive · 4mo ago↗ source
  • Bristol Myers reaches a crossroads as a make-or-break year takes shape
    Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by
    Endpoints · 4mo ago↗ source
  • Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
    Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…
    Endpoints · 4mo ago↗ source
  • FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
    Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…
    BioPharma Dive · 4mo ago↗ source
  • Infant formula largely safe from heavy metals, FDA finds
    FDA sampled 312 major infant formula brands and found low or undetectable levels of pesticide residue, PFAS, heavy metals and phthalates.
    STAT · 4mo ago↗ source
  • After Apellis deal, Biogen looks to fill early-stage pipeline
    Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and res…
    Endpoints · 4mo ago↗ source
  • AstraZeneca rekindles UK relationship, pledges £300M to expand
    AstraZeneca and the UK government are back in each other's good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a £300 million budget to finish construction of a n…
    Endpoints · 4mo ago↗ source
  • STAT+: A patent win for Pfizer and BridgeBio
    A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout
    STAT · 4mo ago↗ source
  • Chiesi signs $1.9B deal to acquire KalVista and its approved drug
    Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…
    Endpoints · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
    The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen
    STAT · 4mo ago↗ source
  • Should pharma be swinging bigger with AI? One top researcher wants to try
    RIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Internati…
    Endpoints · 4mo ago↗ source
  • Food safety experts warn of USDA brain drain
    An autism advisory committee finally meets again, antipsychotics and dementia, and more health news from Morning Rounds
    STAT · 4mo ago↗ source
  • GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
    GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with…
    Endpoints · 4mo ago↗ source
  • MPM has collected three China drugs for its ‘best of both worlds’ strategy
    MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three…
    Endpoints · 4mo ago↗ source
  • AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy
    AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for.…
    Endpoints · 4mo ago↗ source